Cristiano Ferrario - Concepedia

Author

Cristiano Ferrario

Also Known As

C Ferrario, C. Ferrario, CRISTIANO FERRARIO, Cristiano Ferrario, Cristiano. Ferrario, Ferrario Cristiano, Jennifer Friedmann

234

Publications

7.6K

Citations

H-Index

Concepts

All Affiliations

Jewish General Hospital McGill University Princess Margaret Cancer Centre Dana-Farber Cancer Institute BC Cancer Agency

About

Cristiano Ferrario is an author at Jewish General Hospital specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	21	4.7K
2	Health Sciences	5	5	1.8K
3	Cell Biology	4	4	189
4	Public Health	1	1	31
5	Cardiothoracic Surgery	1	1	10

Cristiano Ferrario

Publications

Citations

H-Index

Page 1

	Year	Citations
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial Javier Cortés, David W. Cescon, Hope S. Rugo, The Lancet Chemotherapy Versus PlaceboBreast OncologyOncologyClinical TrialsBreast Cancer	2020	1.7K
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer Aditya Bardia, Sara A. Hurvitz, Sara M. Tolaney, New England Journal of Medicine	2021	1.4K
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial Elizabeth A. Mittendorf, Hong Zhang, Carlos H. Barrios, The Lancet Breast OncologyOncologyBreast CancerPharmacotherapyCancer Treatment	2020	1K
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu, The Lancet Oncology First-line TherapyUrologyChemotherapy Versus ChemotherapyGenitourinary CancerMedicine	2021	627
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer Charles E. Geyer, Judy E. Garber, Richard D. Gelber, Annals of Oncology Breast OncologyOverall SurvivalMedicinePathologyGermline Pathogenic Variants	2022	404
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial Daniel P. Petrylak, Ronald de Wit, Kim N., The Lancet Platinum-based TherapyUrologyMetastatic Urothelial CarcinomaGenitourinary CancerMedicine	2017	175
Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced <i>ERBB2/HER2</i>-Positive Metastatic Breast Cancer Virginia F. Borges, Cristiano Ferrario, Nathalie Aucoin, JAMA Oncology	2018	162
An integrated genomic approach identifies ARID1A as a candidate tumor-suppressor gene in breast cancer Aline Mamo, Luca Cavallone, Şükrü Tüzmen, Oncogene Tumor BiologyCandidate Tumor-suppressor GeneBreast OncologyMedicineGenetics	2011	123
Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors Alberto Farolfi, Elisabetta Melegari, Michele Aquilina, Heart	2013	106
A Unique Morphological Phenotype in Chemoresistant Triple-Negative Breast Cancer Reveals Metabolic Reprogramming and PLIN4 Expression as a Molecular Vulnerability Isabelle Sirois, Adriana Aguilar‐Mahecha, Josiane Lafleur, Molecular Cancer Research Breast OncologyPlin4 ExpressionMolecular BiologyLipid DropletsMetabolic Remodeling	2019	104

Page 1